Adagrasib is a targeted drug and belongs to which generation

Adagrasib (Adagrasib) is a targeted drug. It targets specific cancer mutated genes and has the effect of inhibiting the growth and spread of cancer cells. Specifically, adagrasib is a KRAS G12C inhibitor that focuses on inhibiting the activity of KRAS G12C mutant proteins, thereby blocking the growth and spread of tumor cells. This characteristic allows adagrasib to demonstrate good efficacy and potential in the treatment of cancers related to KRAS G12C mutations, such as non-small cell lung cancer. Compared with traditional chemotherapy drugs, it will affect normal cells less. This allows adagrasib to provide more effective treatment and reduce many of the side effects associated with traditional chemotherapy.